Journal of General Virology, Vol 79, 1963-1970, Copyright © 1998 by Society for General Microbiology

ARTICLES

Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6

D Gardiol and L Banks
International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.

An important characteristic of the E6 proteins derived from oncogenic associated human papillomaviruses (HPVs) is their ability to target the cellular tumour suppressor protein, p53, for ubiquitin mediated degradation. Several studies have attempted to address the important characteristics of both E6 and p53 for this activity in vitro, but the equivalent determinants have not been extensively assessed in vivo. Indeed, recent studies indicate differences between the in vitro and the in vivo degradation assays. We have performed an extensive analysis of the ability of a range of HPV-18 E6 mutants to direct p53 degradation in vivo. In addition, we have also compared the ability of HPV-18 E6 to direct the degradation of different oligomeric forms of p53 both in human and in murine cells. The results of these studies show that mutants of E6 exhibit very similar phenotypes both in vitro and in vivo. In contrast, mutants of p53 show markedly different susceptibilities in vitro and in vivo to E6-induced degradation, and this is further affected by the nature of the cell type in which the assays are performed. Finally, using a cell line temperature sensitive for the E1 ubiquitin-activating enzyme we have been able to show directly that this enzyme is involved in the process of E6-mediated degradation of p53 in vivo.

This article has been cited by other articles:

				R. B. Park and E. J. Androphy Genetic Analysis of High-Risk E6 in Episomal Maintenance of Human Papillomavirus Genomes in Primary Human Keratinocytes J. Virol., October 11, 2002; 76(22): 11359 - 11364. [Abstract] [Full Text] [PDF]

				D. Gardiol, S. Galizzi, and L. Banks Mutational analysis of the discs large tumour suppressor identifies domains responsible for human papillomavirus type 18 E6-mediated degradation J. Gen. Virol., February 1, 2002; 83(2): 283 - 289. [Abstract] [Full Text] [PDF]

				Y. Y. Degenhardt and S. J. Silverstein Gps2, a Protein Partner for Human Papillomavirus E6 Proteins J. Virol., January 1, 2001; 75(1): 151 - 160. [Abstract] [Full Text]

				M. L. Gillison, W. M. Koch, R. B. Capone, M. Spafford, W. H. Westra, L. Wu, M. L. Zahurak, R. W. Daniel, M. Viglione, D. E. Symer, et al. Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers J Natl Cancer Inst, May 3, 2000; 92(9): 709 - 720. [Abstract] [Full Text] [PDF]

				V. T. K. Chow and P. W. F. Leong Complete nucleotide sequence, genomic organization and phylogenetic analysis of a novel genital human papillomavirus type, HLT7474-S J. Gen. Virol., November 1, 1999; 80(11): 2923 - 2929. [Abstract] [Full Text]